TerminatedNot Applicable

Efficacy of Methimazole Dosing Algorithm

Stopped: Unable to reach recruiting goals

United States11 participantsStarted 2022-02-14

Plain-language summary

To prospectively study the efficacy and safety of the Cook County Health (CCH) methimazole (MMI) dosing algorithm in the setting of new onset Graves' disease.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Non-pregnant adults (\>18 years of age) with new diagnosis of Graves' Disease (elevated free T4, Free T3, low or suppressed TSH, positive TSI and or thyroid eye disease) and * either drug naïve or who have been initiated on MMI within previous 4-6 weeks per CCH algorithm. Exclusion Criteria: * Pregnant patients * hyperthyroidism due to other causes, example - Toxic Multinodular Goiter, Iodine induced thyrotoxicosis, etc. * Graves patients who present with atrial fibrillation, CHF or other end organ damage

What they're measuring

Achievement of euthyroid state

Timeframe: 17 weeks

Trial details

NCT IDNCT05964452

SponsorCook County Health

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2024-09-17

View on ClinicalTrials.gov More Graves Disease trials